JP4074458B2 - Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療 - Google Patents

Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療 Download PDF

Info

Publication number
JP4074458B2
JP4074458B2 JP2001532746A JP2001532746A JP4074458B2 JP 4074458 B2 JP4074458 B2 JP 4074458B2 JP 2001532746 A JP2001532746 A JP 2001532746A JP 2001532746 A JP2001532746 A JP 2001532746A JP 4074458 B2 JP4074458 B2 JP 4074458B2
Authority
JP
Japan
Prior art keywords
rarγ
selective
rar
lung
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001532746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003512418A (ja
Inventor
ベローニ，ポーラ・ナネット
クラウス，ミハエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2003512418A publication Critical patent/JP2003512418A/ja
Application granted granted Critical
Publication of JP4074458B2 publication Critical patent/JP4074458B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001532746A 1999-10-19 2000-10-13 Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療 Expired - Fee Related JP4074458B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19
US60/160,415 1999-10-19
PCT/EP2000/010076 WO2001030326A1 (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007185746A Division JP4850791B2 (ja) 1999-10-19 2007-07-17 Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療

Publications (2)

Publication Number Publication Date
JP2003512418A JP2003512418A (ja) 2003-04-02
JP4074458B2 true JP4074458B2 (ja) 2008-04-09

Family

ID=22576814

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001532746A Expired - Fee Related JP4074458B2 (ja) 1999-10-19 2000-10-13 Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療
JP2007185746A Expired - Fee Related JP4850791B2 (ja) 1999-10-19 2007-07-17 Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007185746A Expired - Fee Related JP4850791B2 (ja) 1999-10-19 2007-07-17 Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療

Country Status (33)

Country Link
US (1) US6300350B1 (enExample)
EP (1) EP1225878B1 (enExample)
JP (2) JP4074458B2 (enExample)
KR (1) KR100485581B1 (enExample)
CN (1) CN1201730C (enExample)
AR (1) AR029648A1 (enExample)
AT (1) ATE344661T1 (enExample)
AU (1) AU777325B2 (enExample)
BR (1) BR0015225A (enExample)
CA (1) CA2387844C (enExample)
CY (1) CY1105941T1 (enExample)
CZ (1) CZ20021657A3 (enExample)
DE (1) DE60031790T2 (enExample)
DK (1) DK1225878T3 (enExample)
ES (1) ES2274810T3 (enExample)
HR (1) HRP20020329A2 (enExample)
HU (1) HUP0203295A3 (enExample)
IL (1) IL149151A0 (enExample)
JO (1) JO2178B1 (enExample)
MA (1) MA26835A1 (enExample)
MX (1) MXPA02003843A (enExample)
MY (1) MY129001A (enExample)
NO (1) NO328738B1 (enExample)
NZ (1) NZ518118A (enExample)
PE (1) PE20010678A1 (enExample)
PL (1) PL357499A1 (enExample)
PT (1) PT1225878E (enExample)
RS (1) RS50165B (enExample)
RU (1) RU2257383C2 (enExample)
TR (1) TR200201071T2 (enExample)
TW (1) TWI288639B (enExample)
WO (1) WO2001030326A1 (enExample)
ZA (1) ZA200202576B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
MXPA04002305A (es) 2001-09-18 2004-06-29 Hoffmann La Roche Agonistas ii de retinoides de urea sustituida.
BR0212583A (pt) * 2001-09-18 2004-10-13 Hoffmann La Roche Agonistas i para retinóides de alquil uréia
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
US20070104809A1 (en) 2003-08-22 2007-05-10 Danisco A/S Composition comprising a bacteriocin and an extract from a plant of the labiatae family
WO2008057930A2 (en) * 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with retinoic acid receptor agonists
CN103200937B (zh) 2010-09-01 2020-07-03 托马斯杰弗逊大学 用于肌肉修复和再生的组合物和方法
AU2012272642B2 (en) 2011-06-24 2017-09-07 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2736332A4 (en) * 2011-07-29 2015-03-18 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
AU2013363215B2 (en) 2012-12-17 2018-03-01 Parion Sciences, Inc. 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
ES2909884T3 (es) 2013-08-20 2022-05-10 Univ Washington Through Its Center For Commercialization Inhibidores nuevos y específicos de la hidroxilasa del ácido retinoico del citocromo P450 26
WO2015041809A2 (en) 2013-08-26 2015-03-26 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
CZ287771B6 (en) * 1993-08-19 2001-01-17 Janssen Pharmaceutica Nv Dihydrobenzopyran derivatives, process and intermediates for their preparation, their use and pharmaceutical preparations based thereon
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
DE69604713T2 (de) * 1995-02-24 2000-06-21 F. Hoffmann-La Roche Ag, Basel Retinoide
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
ZA9810122B (en) * 1997-11-12 1999-05-12 Hoffmann La Roche Treatment of T-helper cell type 2 mediated immune diseases
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
WO2000061182A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
EP1206436B1 (en) * 1999-08-02 2004-10-13 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
JP4850791B2 (ja) 2012-01-11
JP2007302689A (ja) 2007-11-22
RU2257383C2 (ru) 2005-07-27
AU777325B2 (en) 2004-10-14
HK1051002A1 (zh) 2003-07-18
ATE344661T1 (de) 2006-11-15
DE60031790T2 (de) 2007-09-20
MXPA02003843A (es) 2002-09-30
CZ20021657A3 (cs) 2002-10-16
NO20021823L (no) 2002-04-18
RS50165B (sr) 2009-05-06
NO20021823D0 (no) 2002-04-18
CA2387844C (en) 2009-04-14
CY1105941T1 (el) 2011-04-06
IL149151A0 (en) 2002-11-10
NO328738B1 (no) 2010-05-03
AU1137401A (en) 2001-05-08
ZA200202576B (en) 2003-09-23
PL357499A1 (pl) 2004-07-26
CN1201730C (zh) 2005-05-18
BR0015225A (pt) 2002-07-16
HRP20020329A2 (en) 2004-04-30
EP1225878B1 (en) 2006-11-08
ES2274810T3 (es) 2007-06-01
WO2001030326A1 (en) 2001-05-03
EP1225878A1 (en) 2002-07-31
HUP0203295A3 (en) 2003-04-28
PE20010678A1 (es) 2001-07-04
AR029648A1 (es) 2003-07-10
HUP0203295A2 (hu) 2003-01-28
PT1225878E (pt) 2007-01-31
YU29002A (sh) 2005-06-10
US6300350B1 (en) 2001-10-09
JP2003512418A (ja) 2003-04-02
CN1382042A (zh) 2002-11-27
MA26835A1 (fr) 2004-12-20
DK1225878T3 (da) 2007-03-05
KR100485581B1 (ko) 2005-04-27
JO2178B1 (en) 2003-04-23
DE60031790D1 (de) 2006-12-21
MY129001A (en) 2007-03-30
CA2387844A1 (en) 2001-05-03
TR200201071T2 (tr) 2002-08-21
NZ518118A (en) 2004-02-27
KR20020043640A (ko) 2002-06-10
TWI288639B (en) 2007-10-21

Similar Documents

Publication Publication Date Title
JP4850791B2 (ja) Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療
JPH013193A (ja) 細胞、組織修復剤
US6339107B1 (en) Methods for treatment of Emphysema using 13-cis retinoic acid
JPH09506622A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノキサリン化合物
CN119606938B (zh) 绿原酸在制备预防和治疗主动脉夹层药物中的应用
AU735382B2 (en) Use of alpha-rar antagonists for inhibition of mucin secretion
CN119055627A (zh) 绿原酸在制备预防和治疗主动脉夹层药物中的应用
MX2008011148A (es) Metodo y composicion para tratar enfermedad pulmonar obstructiva cronica.
HK1051002B (en) Treatment of emphysema using rar selective retinoid agonists
CN114306299A (zh) 贝利司他在制备缓解和/或治疗缺血性脑卒中药物中的应用
WO2006034495A2 (en) Methods of using menthol propyleneglycol-carbonate and analogs thereof for producing anti-inflammatory and anti-angiogenic effects
US20120295982A1 (en) Treating human male copd patients with oral bedoradrine
MXPA00008580A (en) Use of alpha-rar antagonists for inhibition of mucin secretion

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070717

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080125

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110201

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120201

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130201

Year of fee payment: 5

LAPS Cancellation because of no payment of annual fees